| abstract |
Provided is a pharmaceutical composition including a core in the form of a multiple unit spheroid (MUST) tablet containing esomeprazole or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition dissolves 50 percent (%) or more within a 15 minute period of an in vitro dissolution test; and a method for preparing the pharmaceutical composition. Accordingly, in case the pharmaceutical composition is developed as the multi-unit spheroid tablet, the dissolution may be accelerated in a condition of a slow stirring rate as compared with a conventional single tablet or pellet formulation. In addition, drugs based on proton pump inhibitors (PPI), including esomeprazole, can be dissociated by gastric acid that has a low pH, which consequently induces a reduction in drug bioavailability, but the pharmaceutical composition hereby can minimize this. |